Boundless Bio Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$64MTTM through 30 Jun 2026
Free Cash Flow -$56.7MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
-64.8%ROE
-39.7%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio9.48x
Net Debt-$44.6Mnet cash position
Cash & Equivalents$20.2M
Quality Metrics
Altman Z-Score-2.55
Piotroski F-Score1 / 9
Earnings-Beat Rate0.0%
Multi-Year Trend
Diluted EPS-$2.85TTMFY2025: $-2.60
Dividend
No dividend
Capital Allocation
R&D Spend$44.2M
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.